This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: G11.8 / G11.9 | Special Copayment Reduction: V123 |
| B. Synonyms | Other hereditary ataxias (G11.8), hereditary ataxia, unspecified (G11.9), hereditary cerebellar degeneration, hereditary cerebellar disease, hereditary cerebellar syndrome, hereditary cerebellar ataxia NOS |
| C. Adult onset | Possibility of first onset in adulthood: moderate — onset varies from childhood to adulthood depending on the disease type included |
| 1. History | Meaning and role of the G11.8/G11.9 codes; clinical and genetic advances in unclassified hereditary ataxias |
| 2. Causes | Hereditary ataxia gene mutations without an assigned specific code; cerebellar degeneration with unidentified gene |
| 3. Genetics | Heterogeneous group; various inheritance patterns including autosomal, X-linked, and mitochondrial |
| 4. General epidemiology | About 30–50% of all hereditary ataxias have no identified causative gene; age of onset and sex ratio vary |
| 5. Pathophysiology | Degeneration of the cerebellar cortex, dentate nucleus, and spinocerebellar tracts; various cellular mechanisms (axonal transport, oxidative stress, ion channels) |
| 6. Symptoms | Progressive cerebellar ataxia + various accompanying symptoms by subtype; multisystem neurological involvement possible |
| 7. Signs | Standard signs of cerebellar ataxia; subtypes differentiated by accompanying neurological signs |
| 8. Screening | Clinical exome/genome sequencing after a negative known-gene panel, metabolic tests, MRI |
| 9. Diagnosis | Detailed classification of clinical phenotype, comprehensive NGS-based genetic approach, regular re-evaluation |
| 10. Treatment | Focus on symptomatic treatment, rehabilitation therapy, review of possible specific treatment depending on the gene found |
| 11. Prognosis | Varies by included subtype; prognosis difficult to predict when cause unidentified; generally progressive course |
| 12. Prevention | Genetic counseling, prenatal and preimplantation diagnosis when causative gene identified, prevention of complications |
| 13. References | Mancuso M et al. Eur J Neurol 2014 and 9 other papers |
The ICD-10 codes G11.8 ("Other hereditary ataxias") and G11.9 ("Hereditary ataxia, unspecified") are residual codes covering hereditary ataxias for which no specific genotype or syndromic diagnosis code has been assigned. This category was created to accommodate the many patients who, during the period before molecular genetics developed, could be presumed clinically to have a hereditary condition but for whom there was no specific code.
Looking at the history of the classification of hereditary ataxias, before Harding's clinical classification in the 1980s, autosomal dominant cerebellar ataxia (ADCA) was described as a very heterogeneous group, and until individual genotypes were identified, diagnosis relied on family history and clinical features. Even after major subtypes such as Friedreich ataxia and SCA1–3 were identified, many patients remained gene-test negative, and these were classified under the G11.8/G11.9 codes.
Since the 2000s, with advances in next-generation sequencing (NGS) technology, especially the spread of clinical exome sequencing and genome sequencing, new gene variants are being found in a considerable proportion of patients whose cause was previously unidentified. Recently discovered genes such as SCA27B (FGF14 GAA expansion), STUB1 (SCA48), and RFC1 (part of CANVAS syndrome) are being identified in patients previously classified as G11.8/G11.9. With these advances, the frequency of use of this residual code is expected to decrease in the future.
The causes of hereditary ataxias included in the G11.8/G11.9 codes can be divided into two categories. The first consists of subtypes in which a specific gene mutation has been identified but which have not been given a separate code in ICD-10. For example, cerebellar ataxia due to POLG gene mutation (mitochondrial DNA polymerase gamma), autosomal recessive cerebellar ataxia type 10 due to ANO10 gene mutation, SYNE1 gene mutation, RNF170, STUB1, and others fall into this category.
The second consists of truly gene-unidentified hereditary ataxias whose cause is not revealed even by comprehensive genetic testing. These are cases with a family history or a strong clinical suspicion of heredity, but in which none of the currently known genes is identified as the cause. Their classification may be reorganized as new genes are discovered in the future.
Other specific subtypes that may be included in this category include seronegative acquired immune-mediated cerebellitis (when a chronic course gives a hereditary-like pattern), CANVAS syndrome (RFC1 gene AAGG intron repeat expansion; triad of cerebellar ataxia + peripheral neuropathy + vestibular disorder), and treatable metabolic ataxias (some of which, such as vitamin E deficiency, coenzyme Q10 deficiency, and abetalipoproteinemia, are hereditary).
Hereditary ataxias included in G11.8/G11.9 encompass various inheritance patterns, including autosomal dominant, autosomal recessive, X-linked recessive, and mitochondrial maternal inheritance. When the cause is not identified, the inheritance pattern is estimated based on the pattern of occurrence within the family.
Cerebellar ataxia due to mitochondrial gene variants (POLG, TWNK, MTTL1, MTTK, etc.) shows maternal inheritance or autosomal recessive inheritance. POLG mutations cause both Alpers-Huttenlocher syndrome, which presents a combined phenotype of cerebellar ataxia, liver dysfunction, and peripheral neuropathy, and adult-onset mtDNA-related ataxias (SANDO, etc.). CANVAS syndrome (RFC1) is autosomal recessive and caused by SAF repeat expansion.
In cerebellar degeneration of unidentified cause, it is often difficult to clearly determine the inheritance pattern. In small families or sporadic cases, it may be difficult to distinguish between autosomal dominant and de novo mutations. In such cases, clinical exome sequencing and parental trio analysis help detect de novo variants. After the gene is identified, risk within the family is reassessed and genetic counseling is provided.
The exact prevalence of patients corresponding to G11.8/G11.9 is difficult to estimate because the definition itself is residual. However, a considerable proportion of hereditary ataxia patients have no cause identified by current standard gene panel testing. Depending on the study, 40–60% of early-onset ataxias and 60–70% of late-onset ataxias remain of unknown cause even after conventional gene panel testing.
Age of onset and clinical phenotype vary greatly depending on the included subtype. Some begin in childhood, others in adulthood or later. CANVAS syndrome mainly begins after the 50s and is characterized by a triad (cerebellar ataxia + peripheral neuropathy + vestibular disorder). RFC1-related CANVAS has been reported in recent studies to account for 10–15% of late-onset ataxias, making it an important diagnostic target. Sex distribution varies by inheritance pattern and is equal except for X-linked forms.
The pathogenic mechanism of hereditary cerebellar degeneration included in G11.8/G11.9 varies depending on the causative gene. Common pathological features are loss of Purkinje cells in the cerebellar cortex, degeneration of neurons in the cerebellar dentate nucleus, and axonal degeneration of the spinocerebellar tracts.
In POLG-related ataxia, loss of function of the mitochondrial DNA replication enzyme leads to accumulation of mtDNA deletions and mutations, and the resulting impairment of mitochondrial energy production causes oxidative damage to cerebellar neurons. Cerebellar Purkinje cells have high energy requirements and are vulnerable to oxidative stress, so they are selectively damaged. In CANVAS, loss of RFC1 function is presumed to affect the RFC complex involved in DNA repair, causing neuronal damage in the dorsal root ganglia, vestibular nerve, and cerebellum.
Even when the cause has not been identified, impaired axonal transport, disturbed protein homeostasis (abnormalities of the proteasome and autophagy pathways), ion channel dysfunction, and increased oxidative stress have been proposed as common pathological mechanisms. Which of these mechanisms predominates in an individual patient can be interpreted after new genes are discovered. Pathological atrophy of the cerebellum, spinal cord, and brainstem is confirmed on MRI, and functional decline deepens as degeneration progresses.
The common symptom of G11.8/G11.9 is progressive cerebellar ataxia. Gait instability, balance disorder, upper-limb incoordination, and dysarthria are the main symptoms. Specific accompanying symptoms of each subtype provide clues to diagnosis.
In POLG-related ataxia, in addition to cerebellar ataxia, multisystem features appear, such as peripheral neuropathy (distal sensory and motor abnormalities), liver dysfunction, seizures, ophthalmoplegia, convulsions, cognitive decline, and hearing loss. The adult-onset form (SANDO: sensory ataxic neuropathy, dysarthria, ophthalmoparesis) is characterized by the triad of sensory neuropathy, dysarthria, and ophthalmoplegia.
CANVAS syndrome is characterized by the triad of cerebellar ataxia, sensory neuropathy (loss of proprioception), and bilateral vestibular hypofunction (vestibular areflexia). It is often accompanied by chronic cough. In ANO10-related ataxia, slowly progressive cerebellar ataxia may be accompanied by cognitive decline and seizures. In STUB1-related ataxia (SCA48), cognitive impairment and parkinsonism may be present. In cases of unidentified cause, a pattern of simple progressive cerebellar atrophy is often seen.
On neurological examination, the standard signs of cerebellar ataxia are observed. Wide-based gait, limb incoordination (dysmetria), intention tremor, oculomotor abnormalities (nystagmus, saccade abnormalities), and dysarthria are the main cerebellar signs. Additional signs of each subtype are important for differentiation.
In POLG-related cases, ophthalmoplegia (especially supranuclear ophthalmoplegia), decreased distal sensation in the lower limbs, and decreased or absent deep tendon reflexes are observed. In CANVAS, persistent imbalance due to bilateral loss of vestibular function (usually positive head impulse test [HIT]), lower-limb sensory neuropathy (loss of vibration sense and proprioception), and cerebellar signs are confirmed as a triad. Marked balance impairment is seen on the Romberg test.
Quantitative ataxia assessment using SARA or ICARS is used to monitor progression. MRI shows the pattern of atrophy of the cerebellar hemispheres, cerebellar vermis, and brainstem, and spinal cord atrophy is also observed in some. In cerebellar degeneration of unidentified cause, MRI findings often do not help diagnose a specific subtype. Electrophysiological tests (nerve conduction, vestibular evoked myogenic potentials, eye movement tracking) are useful for evaluating accompanying peripheral nerve and vestibular abnormalities.
In patients classified as G11.8/G11.9, thorough differential diagnosis is the first step of screening. A standard ataxia gene panel (including Friedreich, SCA1–3/6/7, SCA27B) is performed first, and if negative, further testing proceeds. Depending on the clinical phenotype, when POLG-related disease is suspected, serum lactate and pyruvate, mitochondrial enzyme activity on muscle biopsy, and POLG gene sequencing are needed. When CANVAS is suspected, RFC1 gene repeat expansion analysis, vestibular function tests (caloric test, video head impulse test), and sensory nerve conduction studies are performed.
Elevated serum alpha-fetoprotein (AFP) suggests A-T. Blood tests to exclude treatable causes such as vitamin E, coenzyme Q10, vitamin B12, copper, thyroid function, and antibodies (paraneoplastic, anti-GAD, anti-gliadin) are included in screening. Brain and spinal MRI is essential for evaluating structural causes of ataxia and patterns of atrophy.
If the standard panel is negative, clinical exome sequencing is the next step, and parental trio analysis increases the detection rate of de novo variants. Genome sequencing is advantageous for detecting noncoding-region repeat expansions not detected by exome sequencing (e.g., FGF14 GAA repeat in SCA27B, RFC1 repeat in CANVAS). Plans are established for regular clinical re-evaluation and retesting when new genes are discovered.
G11.9 (hereditary ataxia, unspecified) is a diagnosis applied when heredity is strongly suspected clinically but the cause has not been revealed by currently known genetic testing. G11.8 (other hereditary ataxias) is used when heredity has been confirmed but there is no other specific code within ICD-10. Clinical diagnosis requires confirmation of a progressive course of at least 6–12 months and family history analysis.
The diagnostic process follows a stepwise approach. Step 1: exclude treatable causes (vitamin deficiency, metabolic disease, autoimmunity). Step 2: standard gene panel testing (SCA, Friedreich, CANVAS RFC1, major cerebellar ataxia genes). Step 3: clinical exome sequencing (including parental trio). Step 4: genome sequencing (including noncoding repeat expansions). Step 5: RNA sequencing (detection of splicing variants). Reclassification takes place when new genes are discovered.
On brain MRI, the distribution and pattern of cerebellar atrophy (anterior lobe predominant, posterior lobe predominant, pancerebellar atrophy, cerebellar-brainstem atrophy, etc.) help estimate the subtype. Neuropathological examination (biopsy) is performed for clinical research purposes and confirms the pattern of cerebellar Purkinje cell loss, presence of inclusions, mitochondrial abnormalities, and so on. Interpretation of the pathogenicity of gene variants follows the ACMG/AMP classification criteria.
For most hereditary cerebellar degenerations included in G11.8/G11.9, there is no fundamental cure, and the goals are symptom management and maintenance of function. Rehabilitation therapy (physical, occupational, and speech therapy) is fundamental for all patients. For cerebellar ataxia, acetazolamide and 4-aminopyridine help improve symptoms in some subtypes.
When a treatable cause is identified, specific treatment is possible. In cerebellar ataxia due to coenzyme Q10 deficiency, high-dose CoQ10 supplementation is effective. In vitamin E deficiency (hereditary vitamin E deficiency, TTPA gene mutation), vitamin E supplementation can slow the progression of ataxia. In POLG-related ataxia, valproic acid is contraindicated because it can cause POLG-related hepatotoxicity and worsening of seizures, and alternative anticonvulsants such as levetiracetam are used.
Riluzole has been reported to have some effect in general cerebellar ataxia in small studies. There are recent study results showing symptom improvement with N-acetyl-leucine in several types of cerebellar ataxia. Standard symptomatic treatment for accompanying symptoms (seizures, peripheral neuropathy, bladder dysfunction, cognitive decline) is given concurrently. Cause-specific approaches such as gene therapy become possible through research on the relevant genotype after the causative gene is identified.
The prognosis of patients included in G11.8/G11.9 varies greatly depending on the included genotype and clinical subtype. In general, progressive cerebellar degeneration slowly worsens over decades, eventually leading to functional decline such as inability to walk, speech impairment, and dysphagia. However, the rate of progression and the final degree of disability vary greatly between individuals.
CANVAS syndrome tends to progress relatively slowly, and survival for decades after onset is possible. POLG-related ataxia may have a poor prognosis due to multisystem involvement, and liver dysfunction or worsening seizures are life-threatening. Pure cerebellar degeneration of unidentified cause has a course that differs between individuals, but generally progresses slowly over decades.
When the causative gene is identified, prognosis prediction becomes more accurate, and the possibility of access to new treatments also opens. Early diagnosis, multidisciplinary management, and the exclusion and treatment of treatable causes have an important influence on prognosis. It is important to explain to patients and families the limitations of the current diagnosis and plans for future re-evaluation by genetic testing.
When the causative gene is identified, a prevention strategy is established according to the inheritance pattern. In autosomal dominant forms, 50% of children are at risk of developing the disease, so genetic counseling, predictive genetic testing, PGT-M, or prenatal diagnosis are possible. In autosomal recessive forms, parental carrier testing is performed and used for family planning. In mitochondrial (maternally inherited) forms, transmission from mother to child is possible, and donor eggs or mitochondrial replacement techniques are being studied for its prevention.
When the causative gene is not identified, testing and counseling are offered to family members according to the clinically estimated inheritance pattern. Siblings in the family undergo clinical monitoring to detect early symptom onset, and when the cause is identified, reclassification and a specific management plan are established. For secondary prevention, fall prevention, maintenance of swallowing function, and nutritional management are important. Regular clinical follow-up and plans for retesting when new genes are discovered are needed.